- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05303402
Eine klinische Phase-III-Studie zur Bewertung der Sicherheit und Immunogenität einer COVID-19-Impfstoff-Auffrischungsdosis bei immunsupprimierten Erwachsenen.
Eine offene, einarmige, multizentrische Phase-III-Studie zur Bewertung der Immunogenität und Sicherheit einer zusätzlichen Impfdosis mit einem rekombinanten Protein-RBD-Fusions-Heterodimerkandidaten (PHH-1V) gegen SARS-CoV-2 bei Erwachsenen mit Prä -bestehende immunsuppressive Erkrankungen, die gegen COVID-19 geimpft wurden
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19
Studienübersicht
Detaillierte Beschreibung
This is a phase IIb/III, open label, single arm, multi-center clinical trial that aims to determine safety, reactogenicity, tolerability and immunogenicity of additional vaccination with a recombinant protein receptor binding domain (RBD) fusion heterodimer candidate against SARS-CoV-2 developed by HIPRA (PHH-1V) in individuals with pre-existing immunosuppressive conditions. In this phase III study, approximately 400 eligible individuals who have received primary vaccination against COVID-19 with 3 doses of mRNA vaccine (or 2 doses plus a documented history of COVID) last dose being administered at least 91 days before day 0 will be included. Individuals recruited in Turkey which received a primary vaccination regimen using a combination of Coronavac and Comirnaty will be allowed to be included. A maximum of 50% of Individuals with history of COVID-19 disease will be allowed to be included if diagnosed at least 91 days prior, passed 30 days from hospital discharge prior to inclusion and provided they are no suffering from long covid (Post-acute COVID-19 syndrome). All participants will receive a single dose of PHH-1V on Day 0 and will be observed for 15 minutes, except for those participants reporting previous mild allergy reactions to vaccination will be observed for 30 minutes.
All participants will be provided with a paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited adverse events will be reported through Day 28. SAEs, AESI and MAAE will be reported during all the study.
On-site follow-up visits will be performed on Days 14, 91, 182 and 365.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, Spanien, 08036
- Hospital Clínic de Barcelona
-
-
Girona
-
Girona, Girona, Spanien, 17001
- Hospital Josep Trueta
-
-
-
-
Ankara
-
Ankara, Ankara, Türkei (türkiye), 06230
- Hacettepe University Medical Faculty Hospitals
-
Ankara, Ankara, Türkei (türkiye), 06620
- Ankara University Medical Faculty Hospitals
-
-
Istanbul
-
Istanbul, Istanbul, Türkei (türkiye), 34010
- Koc University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 1 Male, female or transgender, ≥ 18 years old at Day 0.
- 2 Provide inform consent form
- 3 Participant who has: 3 doses of mRNA vaccines / 2 doses of mRNA vaccines and previous COVID-19 infection / 2 doses of Coronavac and 1 Comirnaty, or, 1 Coronavac and 2 Comirnaty
- 4 Participant who has: HIV infection with CD4 Tcells counts <400 / Primary antibody deficiency disorders / Kidney disease on dialysis / Kidney transplant at least >1 year / Auto Immune Disease (AID) in treatment with rituximab
- 5 For a female of childbearing potential, to have a negative pregnancy test at Day 0
- Use of any of these contraception:
- Female: hormonal contraception, intrauterine device, vasectomized partner, sexual abstinence, condom.
- Male: Vasectomized participant, sexual abstinence, condom.
Exclusion Criteria:
- 6 History of anaphylaxis to any prior vaccine
- 7 Participants has received or plans to receive live attenuated vaccines, other not live vaccines, or Vaxzevria or Janssen vaccines.
- 8 Pregnant or breast-feeding at Day 0.
- 9 A confirmed COVID-19 diagnose <90 days prior to vaccination day 0.
- 10 A clinically significant acute illness or fever at screening or 48h before day 0.
- 11 Participant had a surgery requiring hospitalisation and has not received the hospital discharge.
- 12 Participant has an ongoing severe and non-stable psychiatric condition
- 13 Participant has a problematic or risky use of substances including alcohol
- 14 Participant has a bleeding disorder that contraindicates intramuscular injection
- 15 Participant suffering from post-acute COVID-19 syndrome / long COVID
- 16 Participant received any immunotherapy to prevent/treat COVID-19 in the last 90 days
- 17 Participant is already participating in another research involving drug, biologics or device
- 18 Participant has donated ≥450 ml of blood products within 12 weeks before screening
- 19 Participant has any medical condition and/or finding that in the investigator opinion might increase participant risk, interfere with the study or impair interpretation of study data.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose
Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose. |
COVID-19 Vaccine HIPRA, 40 mcg/dose |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Immunogenicity against Omicron, Beta, Delta at Day 0 and Day 14
Zeitfenster: Day 0 and Day 14
|
Changes in neutralising antibodies measured by pseudovirus (or live virus for the HIV cohort*) neutralization against Omicron, Beta and Delta any other relevant Variants of Concern (VOC) in the epidemiologic moment, at Baseline and at Day 14 after administration of HIPRA's vaccine (PHH-1V). |
Day 0 and Day 14
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Immunogenicity against Omicron, Beta, Delta at Day 91, Day 182 and Day 365
Zeitfenster: Day 91, Day 182 and Day 365
|
1. To determine and compare the changes of the immunogenicity measured by pseudovirus (or live virus for the HIV cohort) neutralization against Omicron, Beta and Delta and any other relevant Variants of Concern (VOC) in the epidemiologic moment at Days, 91, 182 and 365, after administration of HIPRA's vaccine (PHH-1V). |
Day 91, Day 182 and Day 365
|
|
Total antibodies
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
To evaluate the immunogenicity measured by means of total antibody against Receptor Binding Domain of the Spike protein of SARS-CoV-2 quantification, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 91, 182 and 365 after administration of HIPRA's vaccine (PHH-1V). |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Safety and tolerability of the booster vaccine
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
To assess the safety and tolerability of PHH-1V as an additional dose in adult individuals with pre-existing immunosuppressive conditions |
Day 0, Day 14, Day 91, Day 182, Day 365
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of SARS-CoV-2 infections
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
Number of participants with SARS-CoV-2 infections ≥14 days after PHH-1V administration. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Number of SARS-CoV-2 severe infections (Severe cases are considered as any episode of COVID-19 requiring ≥ 24hrs of hospitalization.)
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
Number of COVID-19 severe infections ≥14 days after PHH-1V administration. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
Celular immunity
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
Antibody IgG subclasses titre usage and avidity of humoral immunity at Baseline and Days 14, 91, 182 and 365. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
|
T-cell cellullar immunity
Zeitfenster: Day 0, Day 14, Day 91, Day 182, Day 365
|
T-cell mediated phenotype polyclonality with potential cross-reactivity capacity and gene-expression profiles against the SARS-CoV-2 Spike & RBD proteins at Baseline and at Days 14, 91, 182 and 365 in a subset of 50% of participants. |
Day 0, Day 14, Day 91, Day 182, Day 365
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Teresa Prat, Hipra Scientific, S.L.U
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HIPRA-HH-4
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .